Application of Monoclonal Antibodies to Autologous Bone Marrow Transplantation

  • Robert C. BastJr.
  • Jerome Ritz


A number of studies in animal models have suggested that serotherapy might be capable of eliminating small numbers of tumor cells in vivo. Therapeutic activity has been documented using antisera against leukemias, lymphomas, and some solid tumors (Bernstein et al., 1982). However, for many years, trials of serotherapy for human cancer have been limited by the lack of availability of sufficient amounts of high-titered antiserum that does not react with vital host tissues. Recently, some success has been achieved in treating mycosis fungoides and other T-cell neoplasms using heteroantisera reactive with T-cell differentiation antigens (Fisher et al., 1978). Anecdotal accounts have noted responses after the infusion of some alloantisera, but in general serotherapy has had little demonstrable impact on most human cancers (Bernstein et al., 1982).


Pluripotent Stem Cell Chronic Myelogenous Leukemia Total Body Irradiation Chronic GVHD Autologous Bone Marrow Transplantation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Appelbaum, F. R., Fefer, A., Cheever, M. A., Buckner, C. D., Greenberg, P. D., Kaplan, H. G., Storb, R., and Thomas, E., 1981, Treatment of non-Hodgkin’s lymphoma with marrow transplantation in identical twins, Blood 58:509–513.PubMedGoogle Scholar
  2. Bast, R. C., Jr., Knapp, R. C., Mitchell, A. K., Thurston, J. G., Tucker, R. W., and Schlossman, S. F., 1979, Immunotherapy of a murine ovarian carcinoma with Corynebacterium parvum and specific heteroantiserum. I. Activation of peritoneal cells to mediate antibody-dependent cytotoxicity, J. Immunol. 123:1945–1951.PubMedGoogle Scholar
  3. Bast, R. C., Jr., Berek, J. S., Obrist, R., Griffiths, C. T., Berkowitz, R. S., Hacker, N. F., Parker, L., Lagasse, L. D., and Knapp, R. C., 1983a, Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum, Cancer Res. 43:1395–1401.PubMedGoogle Scholar
  4. Bast, R. C., Jr., Maver, C., Lipton, D., DeFabritiis, P., Ritz, J., Nadler, L. M., Sallan, S. E., Nathan, D. G., and Schlossman, S. F., 1983b, Development of a clonogenic assay to measure elimination of malignant cells from human bone marrow using monoclonal antibody and complement (C’), Proc. Am. Assoc. Cancer Res. 24:223.Google Scholar
  5. Bast, R. C., Jr., Ritz, J., Lipton, J. M., Feeney, M., Sallan, S. E., Nathan, D. G., and Schlossman, S. F., 1983c, Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement, Cancer Res. 43:1389–1394.PubMedGoogle Scholar
  6. Bernstein, I., Nowinski, R. C., and Wright, P. W., 1982, Monoclonal antibodies: Prospects for cancer treatment, in: Immunological Approaches to Cancer Therapeutics (E. Mihich, ed.), John Wiley and Sons, New York, pp. 277–298.Google Scholar
  7. Bortin, M. M., Truitt, R. L., Rim, A. A., and Bach, F. H., 1979, Graft-versus-leukemia reactivity induced by alloimmunization without augmentation of graft-versus-host reactivity, Nature 281:490–491.PubMedCrossRefGoogle Scholar
  8. Clavell, L. A., Lipton, J. M., Bast, R. C., Jr., Kudisch, M., Pesando, J. M., Schlossman, S. F., and Ritz, J., 1981, Absence of common ALL antigen on normal bipotent myeloid, erythroid, and granulocyte progenitors, Blood 58:333–336.PubMedGoogle Scholar
  9. Colcher, D., Horan-Hand, P., Nuti, M., and Schlom, J., 1981, Spectrum of monoclonal antibodies reactive with human mammary tumor cells, Proc. Natl. Acad. Sci. USA 78:3199–3203.PubMedCrossRefGoogle Scholar
  10. de Bruin, H. G., Astaldi, A., Leupers, T., van de Griend, R. J., Dooren, L. J., Schellekens, P. A., Tanke, H. J., Roos, M., and Vossen, J. M., 1981, T lymphocyte characteristics in bone marrowtransplanted patients. II. Analysis with monoclonal antibodies, J. Immunol. 127:244–251.PubMedGoogle Scholar
  11. Dicke, K. A., Spitzer, G., Peters, L., McCredie, K. B., Zander, A., Verma, D. A., Vellekoop, L., and Hester, J., 1979, Autologous bone marrow transplantation in relapsed adult acute leukaemia, Lancet 1:514–517.PubMedCrossRefGoogle Scholar
  12. Dillman, R. O., Sobol, R. E., Collins, H., Beauregard, J., and Royston, I., 1982, T101 monoclonal antibody therapy in chronic lymphocytic leukemia, in: Hybridomas in Cancer Diagnosis and Treatment (M. S. Mitchell and H. F. Oettgen, eds.), Progress in Cancer Research and Therapy, Volume 21, Raven Press, New York, pp. 151–172.Google Scholar
  13. Dokhelar, M., Wiels, J., Lipinski, M., Tetaud, C., Devergie, A., Gluckman, E., and Tursz, T., 1981, Natural killer cell activity in human bone marrow recipients, Transplantation 31:61–65.PubMedCrossRefGoogle Scholar
  14. Economou, J. S., Shin, H. S., Kaizer, H., Santos, G. W., and Schron, D. S., 1978, Bone marrow transplantation in cancer therapy: Inactivation by antibody and complement of tumor cells in mouse syngeneic marrow transplants (40223), Proc. Soc. Exp. Biol. Med. 158:449–453.PubMedGoogle Scholar
  15. Engelmann, E. G., Warnke, R., Fox, R. I., and Levy, R., 1981, Studies of a human T lymphocyte antigen recognized by a monoclonal antibody, Proc. Natl. Acad. Sci. USA 78:1791–1795.CrossRefGoogle Scholar
  16. Feeney, M., Knapp, R. C., Greenberger, J. S., and Bast, R. C., Jr., 1981, Elimination of leukemic cells from rat bone marrow using antibody and complement, Cancer Res. 41:3331–3335.PubMedGoogle Scholar
  17. Fefer, A., Einstein, A. B., Thomas, E. D., Buchner, D., Clift, R. A., Gluckberg, H., Neiman, P. E., and Storb, R., 1974, Bone marrow transplantation for hematologic neoplasia in 16 patients with identical twins, N. Engl. J. Med. 290:1389–1393.PubMedCrossRefGoogle Scholar
  18. Fisher, R. I., Kubota, T. T., Mandell, G. L., Broder, S., and Young, R. C., 1978, Regression of a T cell lymphoma after administration of anti-thymocyte globulin, Ann. Int. Med. 88:799–800.PubMedGoogle Scholar
  19. Greaves, M. F., Brown, G., Rapson, N. T., and Lister, T. A., 1975, Antisera to acute lymphoblastic leukemia cells, Clin. Immunol. Immunopathol. 4:67–84.PubMedCrossRefGoogle Scholar
  20. Greenberger, J. S., Rosenthal, D. S., Aaronson, S. A., and Maloney, W. C., 1975, Acute myelogenous leukemia of the Wistar/Furth rat: Establishment of a continuous tissue culture line producing lymphoma in vitro and in vivo, Blood 46:27–38.PubMedGoogle Scholar
  21. Hercend, T., Nadler, L. M., Pesando, J. M., Reinherz, E. L., Schlossman, S. F., and Ritz, J., 1981a, Expression of a 26,000 dalton glycoprotein on activated human T cells, Cell. Immunol. 64:192–199.PubMedCrossRefGoogle Scholar
  22. Hercend, T., Ritz, J., Schlossman, S. F., and Reinherz, E. L., 1981b, Comparative expression of T9, T10 and Ia antigens on activated human T cell subsets, Hum. Immunol. 3:247–259.PubMedCrossRefGoogle Scholar
  23. Hersh, E. M., Murphy, S. G., Gutterman, J. V., Morgan, J., Quesada, J., Zander, A., and Stewart, D., 1982, Antibody dependent cell mediated cytotoxicity in human cancer: Characterization of patient leukocyte activity and treatment effects, Cancer 49:251–260.PubMedCrossRefGoogle Scholar
  24. Hokland, P., Rosenthal, P., Griffin, J. D., Nadler, L. M., Daley, J. F., Hokland, M., Schlossman, S. F., and Ritz, J., 1983, Purification and characterization of fetal hematopoietic cells which express the common acute lymphoblastic leukemia antigen (CALLA), J. Exp. Med. 157:114–129.PubMedCrossRefGoogle Scholar
  25. Johnson, F. L., Thomas, E. D., Clark, B. S., Chard, R. L., Hartmann, J. R., and Storb, R., 1981, A comparison of marrow transplantation with chemotherapy for children with acute lymphoblastic leukemia in second or subsequent remission, N. Engl. J. Med. 305:846–851.PubMedCrossRefGoogle Scholar
  26. Kaizer, H., Wharam, M. D., Johnson, R. J., et al., 1980, Requirements for the successful application of autologous bone marrow transplantation in the treatment of selected malignancies, Blut. (Suppl.) 25:285.Google Scholar
  27. Kersey, J. H., 1981, Lymphoid progenitor cells and acute lymphoblastic leukemia: Studies with monoclonal antibodies, J. Clin. Immunol. 1:201–207.CrossRefGoogle Scholar
  28. Kohler, G., and Milstein, C., 1975, Continuous cultures of fixed cells secreting antibody of predefined specificity, Nature 256:495–497.PubMedCrossRefGoogle Scholar
  29. Krolick, K. A., Uhr, J. W., and Vitetta, E. S., 1982, Selective killing of leukaemic cells by antibody-toxin conjugates: Implications for autologous bone marrow transplantation, Nature 295:604–605.PubMedCrossRefGoogle Scholar
  30. McFarland, W., Granville, N. B., and Dameshek, W., 1959, Autologous bone marrow infusion as an adjunct in therapy of malignant disease, Blood 14:503–521.PubMedGoogle Scholar
  31. Metzgar, R. S., Borowitz, M. J., Jones, N. H., and Dowell, B. L., 1981, The distribution of common acute lymphoblastic leukemia antigen (CALLA) in nonhematopoietic tissues, J. Exp. Med. 154:1249–1254.PubMedCrossRefGoogle Scholar
  32. Miller, R. A., Maloney, D. G., Warnke, R., McDougall, R., Wood, G., Kawakami, T., Dilley, J., Goris, M. L., and Levy, R., 1982, Considerations for treatment with hybridoma antibodies, in: Hybridomas in Cancer Diagnosis and Treatment (M. S. Mitchell and H. F. Oettgen, eds.), Progress in Cancer Research and Therapy, Volume 21, Raven Press, New York, pp. 133–146.Google Scholar
  33. Mitchell, M. S., and Oettgen, H. F. (eds.), 1982, Hybridomas in Cancer Diagnosis and Treatment, Progress in Cancer Research and Therapy, Volume 21, Raven Press, New York.Google Scholar
  34. Nadler, L. M., Stashenko, P., Hardy, R., Kaplan, W. D., Button, L. N., Kufe, D. W., Antman, K. H., and Schlossman, S. F., 1980, Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen, Cancer Res. 40:3147–3154.PubMedGoogle Scholar
  35. Nadler, L. M., Stashenko, P., Ritz, J., Hardy, R., Pesando, J. M., and Schlossman, S. F., 1981, A unique cell surface antigen identifying lymphoid malignancies of B cell origin, J. Clin. Invest. 67:134–140.PubMedCrossRefGoogle Scholar
  36. Netzel, B., Rodt, H., Haas, R. J., Kolb, H. J., and Thierfelder, S., 1980, Immunological conditioning of bone marrow for autotransplantation in childhood acute lymphoblastic leukemia, Lancet 1:1330–1332.PubMedCrossRefGoogle Scholar
  37. Raso, V., Ritz, J., Basala, M., and Schlossman, S. F., 1982, Monoclonal antibodyricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen, Cancer Res. 42:457–464.PubMedGoogle Scholar
  38. Reif, A. E., and Kim, C. H., 1969, Therapy of transplanted mouse leukemias with antileukemia sera, Nature 223:1377–1379.PubMedCrossRefGoogle Scholar
  39. Reinherz, E. L., and Schlossmann, S. F., 1980, The differentiation and function of human T lymphocytes: A review, Cell 19:821–827.PubMedCrossRefGoogle Scholar
  40. Reinherz, E. L., Parkman, R., Rappeport, J., Rosen, F. S., and Schlossman, S. F., 1979, Aberrations of suppressor T cells in human graft-versus-host disease, N. Engl. J. Med. 300:1061–1067.PubMedCrossRefGoogle Scholar
  41. Ritz, J., and Griffin, J. D., 1982, Cell-surface antigens in acute leukemia, in: Biological Responses in Cancer: Progress toward Potential Applcations, Volume 1 (E. Mihich, ed.), Plenum Press, New York, pp. 1–21.CrossRefGoogle Scholar
  42. Ritz, J., and Schlossman, S. F., 1982, Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma, Blood 59:1.PubMedGoogle Scholar
  43. Ritz, J., Pesando, J. M., Notis-McConarty, J., Lazarus, H., and Schlossman, S. F., 1980, A monoclonal antibody to human acute lymphoblastic leukemia antigen, Nature 283:583–585.PubMedCrossRefGoogle Scholar
  44. Ritz, J., Pesando, J. M., Notis-McConarty, J., and Schlossman, S. F., 1980b, Modulation of human acute lymphoblastic leukemia antigen induced by monoclonal antibody in vitro, J. Immunol. 125:1506–1514.PubMedGoogle Scholar
  45. Ritz, J., Nadler, L. M., Bhan, A. K., Notis-McConarty, J., Pesando, J. M., and Schlossman, S. F., 1981a, Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of the B-cell and T-cell lineage, Blood 58:648–652.PubMedGoogle Scholar
  46. Ritz, J., Pesando, J. M., Sallan, S. E., Clavell, L. A., Notis-McConarty, J., Rosenthal, P., and Schlossman, S. F., 1981b, Serotherapy of acute lymphoblastic leukemia with monoclonal antibody, Blood 58:141–152.PubMedGoogle Scholar
  47. Ritz, J., Sallan, S. E., Bast, R. C., Jr., Lipton, J., Clavell, L., Sallan, S. E., Feeney, M., Hercend, T., Nathan, D. G., and Schlossman, S. F., 1982, Autologous bone marrow transplantation in CALLA positive acute lymphoblastic leukemia after in vitro treatment with J5 monoclonal antibody and complement, Lancet 2:60–63.PubMedCrossRefGoogle Scholar
  48. Sallan, S. E., Bast, R. C., Jr., Lipton, J. M., Schlossman, S. F., Nathan, D. G., and Ritz, J., 1982, Autologous bone marrow transplantation in childhood acute lymphoblastic leukemia (ALL), Blood (Suppl.) 60:172A.Google Scholar
  49. Santos, G. W., and Kaizer, H., 1982, Bone marrow transplantation in acute leukemia, Semin. Hematol. 19:227–239.Google Scholar
  50. Schabel, F. M., Jr., Laster, W. R., Jr., Trader, M. W., Corbett, T. H., and Griswold, D. P., Jr., 1981, Combination chemotherapy with nitrosoureas plus other anticancer drugs against animal tumors, in: Nitrosoureas: Current Status and New Developments (A. W. Prestayko, S. T. Crooke, C. H. Baker, S. K. Carter, and P. S. Schein, eds.), Academic Press, New York, pp. 9–26.Google Scholar
  51. Sharkis, S. J., Santos, G. W., and Colvin, M., 1980, Elimination of acute myelogenous leukemia cells from marrow and tumor suspensions in the rat with 4-hydroperoxycyclophosphamide, Blood 55:521–523.PubMedGoogle Scholar
  52. Shin, H. S., Johnson, R. J., Pasternack, G. R., and Economou, J. S., 1978, Mechanisms of tumor immunity: The role of antibody and nonimmune effectors, Prog. Allergy 25:163–210.PubMedGoogle Scholar
  53. Thierfelder, S., Rodt, H., and Netzel, B., 1977, Transplantation of syngeneic bone marrow incubated with leucocyte antibodies, Transplantation 23:459–463.PubMedCrossRefGoogle Scholar
  54. Thorpe, P. E., Mason, D. W., Brown, A. N. F., Simmonds, S. J., Ross, W. C. J., Cumber, A. J., and Forrester, J. A., 1982, Selective killing of malignant cells on a leukaemic rat bone marrow using an antibody-ricin conjugate, Nature 297:594–596.PubMedCrossRefGoogle Scholar
  55. Trigg, M. E., and Poplack, D. G., 1982, Transplantation of leukemic bone marrow treated with cytotoxic anti-leukemic antibodies and complement, Science 217:259–261.PubMedCrossRefGoogle Scholar
  56. Vogel, C., and Muller-Eberhard, H., 1981, Induction of immune cytolysis: Tumor cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3JC5 convertase, Proc. Natl Acad. Sci. USA 78:7707–7711.PubMedCrossRefGoogle Scholar
  57. Weiden, P. L., Flournoy, N., Thomas, E. D., Prentice, R., Fefer, A., Buckner, C. D., and Storb, R., 1979, Anti-leukemic effect of graft-versus-host disease in human recipients of allogeneicmarrow grafts, N. Engl. J. Med. 300:1068–1073.PubMedCrossRefGoogle Scholar
  58. Weiden, P. L., Sullivan, K. M., Flournoy, N., Storb, R., and Thomas, E. D., 1981, Anti-leukemic effect of chronic graft-versus-host disease, N. Engl. J. Med. 304:1529–33.PubMedCrossRefGoogle Scholar
  59. Wells, J. R., Billing, R., Herzog, R., Feig, S. A., Gale, R. P., Terasaki, P., and Cline, M., 1979, Autotransplantation after in vitro immunotherapy of lymphoblastic leukemia, Exp. Hematol. 7:164–169.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • Robert C. BastJr.
    • 1
    • 2
    • 3
  • Jerome Ritz
    • 1
    • 2
    • 3
  1. 1.Divisions of Tumor Immunology and MedicineDana-Farber Cancer InstituteBostonUSA
  2. 2.Department of MedicineBrigham and Women’s HospitalBostonUSA
  3. 3.Department of MedicineHarvard Medical SchoolBostonUSA

Personalised recommendations